

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bayzed Health Group Inc
佰澤醫療集團

(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 2609)

(1) APPOINTMENT OF PRESIDENT
(2) RESIGNATION OF ASSISTANT PRESIDENT

APPOINTMENT OF PRESIDENT

The board (the “**Board**”) of directors (the “**Directors**”) of Bayzed Health Group Inc (the “**Company**”, together with its subsidiaries collectively referred to as the “**Group**”) is pleased to announce that Mr. Lyu Chao (“**Mr. Lyu**”) has been appointed as the president of the Company with effect from December 29, 2025.

The biographical details of Mr. Lyu are set out below:

Mr. Lyu Chao, aged 41, has been appointed as the president of the Company with effect from December 29, 2025. Mr. Lyu is currently the assistant to the president of the Company and the assistant to the chairman of the Board, positions he held since September 22, 2025.

Mr. Lyu has over 16 years of extensive experience in corporate strategic management, investment and financing operations, financial system development, and the development of the healthcare industry. He has served in senior positions at a number of large-scale state-owned enterprises, listed companies, and international institutions, possessing profound industry expertise and outstanding comprehensive management capabilities.

Prior to joining the Group, during April 2022 to October 2023, Mr. Lyu served as a co-president and general manager of the asset management department of Fosun Hive, where he held positions including co-president and chief financial officer and chief investment officer. He oversaw the investment and financing center, planning & finance department, and subsidiary operations, and was fully involved in the integrated management of investment, financing, asset management, and divestment within the health and wellness and various commercial asset sectors.

During September 2019 to July 2021, Mr. Lyu served as the vice president and chief financial officer of Kaisa Health Group Holdings Limited, a company whose shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 876.HK), where he was responsible for investment and financing, financial management, and the medical services segment.

During June 2012 to May 2019, Mr. Lyu served as the provincial platform financial controller of China Resources Pharmaceutical Group Limited, a company whose shares are listed on the Stock Exchange (stock code: 3320), and as the co-general manager of the strategic investment department of both China Resources Pharmaceutical Group Limited and China Resources Medical Holdings Company Limited, a company whose shares are listed on the Stock Exchange (stock code: 1515). He was deeply involved in public hospital reform, university-enterprise cooperation, the restructuring of state-owned enterprise hospitals, and domestic and international capital operation projects.

During January 2009 to June 2012, Mr. Lyu worked at KPMG Huazhen (Guangzhou) and KPMG Hong Kong, participating in audit and special advisory projects for listed companies across various industries.

Mr. Lyu obtained a bachelor’s degree in Accounting from Guangdong University of Foreign Studies in the People’s Republic of China in 2008 and a master degree in business administration from the University of California, USA in 2014. Mr. Lyu holds several professional qualifications including senior accountant and senior financial manager. He is a member of the Institute of Public Accountants (MIPA) and the International Federation of Accountants (IFAC). He is also a U.S. Certified Forensic Public Accountant (FCPA), a Personal Member of the Chinese Institute of Chief Financial Officers, a China Tax Accountant, a China Certified Risk Manager (CRM), and a Member of the National Society of Tax Professionals (NSTP).

Mr. Lyu has entered into a service contract with the Company commencing on December 29, 2025 for three years. Pursuant to the service contract, Mr. Lyu is entitled to an annual remuneration of RMB1.2 million as the president of the Company. His remuneration package was determined by the Board on the recommendation of Remuneration Committee by reference to his qualifications, experience and duties and responsibilities as well as the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Lyu (i) does not hold any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other position with the Company and other members of the Group or other major appointments and professional qualifications; (iii) does not have any relationship with other directors, senior management, substantial or controlling shareholders of the Company; and (iv) does not have any interests in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong).

As of the date of this announcement, Mr. Lyu does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

Save as disclosed above, there are no other matters concerning the Appointments that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to wishes Mr. Lyu every success in his new role.

RESIGNATION OF ASSISTANT PRESIDENT

The Board further announces that Dr. Jiang Zheng (姜錚) (“**Dr. Jiang**”) resigned as an assistant president of the Company with effect from December 29, 2025, due to his desire to devote more time on family matters.

Dr. Jiang has confirmed that he has no disagreement with the Board and that there are no other matters relating to his resignation that need to be brought to the attention of the Company’s shareholders and The Stock Exchange of Hong Kong Limited.

By order of the Board
Bayzed Health Group Inc
(佰澤醫療集團)
Dr. Chen Haoyang
Chairman and Executive Director

Hong Kong, December 29, 2025

As at the date of this announcement, the Board comprises executive Directors of Dr. Chen Haoyang, Mr. Zhao Yongkai, Ms. Xu Xu, Mr. Lu Jizhong and Mr. Feng Yu; and independent non-executive Directors of Mr. Chan Hok Leung, Ms. Liu Shuang and Dr. Guo Wei.